Abstract
Fifty-three premenopausal patients presenting with advanced breast cancer have been treated with a potent new luteinising hormone-releasing hormone agonist Zoladex (ICI 118630) in a phase I clinical trial. On progression of disease 26 patients have undergone therapeutic oophorectomy. We present the clinical and endocrinological responses to treatment in 45 assessable patients. The response rate to Zoladex in this series was 31% and the ER status of the primary tumour was predictive of a response to the luteinising hormone-releasing hormone.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Corbin A. From contraception to cancer: a review of the therapeutic applications of LHRH analogues as antitumor agents. Yale J Biol Med. 1982 Jan-Feb;55(1):27–47. [PMC free article] [PubMed] [Google Scholar]
- Hayward J. L., Carbone P. P., Heuson J. C., Kumaoka S., Segaloff A., Rubens R. D. Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland. Cancer. 1977 Mar;39(3):1289–1294. doi: 10.1002/1097-0142(197703)39:3<1289::aid-cncr2820390340>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
- KENNEDY B. J., MIELKE P. W., Jr, FORTUNY I. E. THERAPEUTIC CASTRATION VERSUS PROPHYLACTIC CASTRATION IN BREAST CANCER. Surg Gynecol Obstet. 1964 Mar;118:524–540. [PubMed] [Google Scholar]
- Klijn J. G. Long-term LHRH-agonist treatment in metastatic breast cancer as a single treatment and in combination with other additive endocrine treatments. Med Oncol Tumor Pharmacother. 1984;1(2):123–128. doi: 10.1007/BF02934984. [DOI] [PubMed] [Google Scholar]
- Maynard P. V., Nicholson R. I. Effects of high doses of a series of new luteinizing hormone-releasing hormone analogues in intact female rats. Br J Cancer. 1979 Mar;39(3):274–279. doi: 10.1038/bjc.1979.51. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Nicholson R. I., Maynard P. V. Anti-tumour activity of ICI 118630, a new potent luteinizing hormone-releasing hormone agonist. Br J Cancer. 1979 Mar;39(3):268–273. doi: 10.1038/bjc.1979.50. [DOI] [PMC free article] [PubMed] [Google Scholar]